Roivant units Urovant, Dermavant in deals as NEA’s Torti joins ‘vant’ team

Two Roivant Sciences GmbH (Basel, Switzerland) subsidiaries struck deals on Tuesday, with Urovant Sciences gaining rights to a gene therapy for overactive bladder and Dermavant Sciences receiving a $100 million investment tied to its tapinarof.

The deals came as Roivant hired New Enterprise Associates Partner Frank Torti as vant investment chair. Torti, who had been with the firm since 2007, specialized in biopharma, medical devices and healthcare services/IT investments...